Breaking News Instant updates and real-time market news.

AXGN

AxoGen

$33.30

-0.39 (-1.16%)

07:27
11/14/18
11/14
07:27
11/14/18
07:27

AxoGen initiated with a Neutral at BTIG

BTIG analyst Ryan Zimmerman initiated AxoGen with a Neutral rating, saying that while the company has been "one of the best growth stories in small-cap MedTech", its valuation appears to be fair. The analyst is positive on the company's peripheral nerve repair products which, as he claims, show "superiority against the standard of care". Zimmerman also points to AxoGen's market opportunity in breast, pain, and oral/maxillofacial surgery areas that imply a runway for AxoGen's future revenue growth.

  • 19

    Nov

AXGN AxoGen
$33.30

-0.39 (-1.16%)

10/30/18
JEFF
10/30/18
NO CHANGE
Target $45
JEFF
Buy
AxoGen remains a top growth idea at Jefferies
Jefferies analyst Raj Denhoy says that after a couple of "choppy quarters," AxoGen posted 41% revenue growth in Q3 and kept 2018 guidance at greater than 40%. The outlook for 2019 was offered up as "at least 35%," which keeps AxoGen among the best medtech growth companies, Denhoy tells investors in a post-earnings research note. He sees an upward bias to 2019 estimates and says the company remains a top growth idea with a Buy rating and $45 price target.
10/30/18
LEER
10/30/18
NO CHANGE
Target $55
LEER
Outperform
AxoGen price target lowered to $55 from $60 at Leerink
Leerink analyst Richard Newitter lowered his price target for AxoGen to $55 from $60, while reiterating an Outperform rating on the shares as he is encouraged by the company's return to over 40% growth in Q3. Further, the analyst believes the company has significant runway ahead to drive increased adoption into a large underpenetrated existing commercially targeted $2.2B "core" peripheral nerve repair opportunity.
09/17/18
JEFF
09/17/18
NO CHANGE
Target $45
JEFF
Buy
AxoGen outlook still 'very compelling' despite share selloff, says Jefferies
Despite the recent pullback in the shares, AxoGen's outlook "remains unchanged and very compelling," Jefferies analyst Raj Denhoy tells investors in a research note after meeting with the company, competitors, and surgeons at the American Society for the Surgery of the Hand Annual Meeting. Surgeon acceptance of the company's technologies is increasing, competitors "are more noise than real," and recent execution issues seem resolved, the analyst contends. He believes AxoGen is one of the best positioned growth medtech names and keeps a Buy rating on the shares with a $45 price target.
09/17/18
CANT
09/17/18
NO CHANGE
Target $45
CANT
Overweight
AxoGen 22% selloff since Sept. 4 is overdone, says Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou views the 22% selloff in shares of AxoGen (AXGN) since September 4, which he attributes to investor concerns about increased competition from Integra LifeSciences (IART) and and Baxter (BAX), as a buying opportunity. The selloff is overdone and provides an attractive entry point for one of the most compelling long-term growth stories in medtech, Bijou tells investors in a research note. After spending time with management, the analyst thinks that AxoGen can deliver on its 2018 sales growth guidance of 40%-plus. He reiterates an Overweight rating on the shares with a $45 price target.

TODAY'S FREE FLY STORIES

ALSN

Allison Transmission

$43.06

-0.96 (-2.18%)

15:30
08/23/19
08/23
15:30
08/23/19
15:30
Conference/Events
Allison Transmission management to meet with RBC Capital »

Meeting to be held In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

15:30
08/23/19
08/23
15:30
08/23/19
15:30
General news
Treasury Action: bond yields have inched up from intraday lows »

Treasury Action: bond…

IWM

iShares Trust Russell 2000 Index Fund

$146.13

-3.92 (-2.61%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:22
08/23/19
08/23
15:22
08/23/19
15:22
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT) at…

IWM

iShares Trust Russell 2000 Index Fund

$146.13

-3.92 (-2.61%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/23/19
08/23
15:17
08/23/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/23/19
08/23
15:16
08/23/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$12.53

-0.24 (-1.88%)

15:15
08/23/19
08/23
15:15
08/23/19
15:15
Options
Fiat Chrysler put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.78

-6.58 (-2.25%)

15:12
08/23/19
08/23
15:12
08/23/19
15:12
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

At time of writing the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.78

-6.58 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDOG

Datadog

$0.00

(0.00%)

15:11
08/23/19
08/23
15:11
08/23/19
15:11
Syndicate
Datadog files S-1 for IPO, seeks to list on Nasdaq with symbol 'DDOG' »

Datadog filed an S-1 with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$18.17

-0.87 (-4.57%)

15:05
08/23/19
08/23
15:05
08/23/19
15:05
Options
Health Insurance Innovations call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 20

    Sep

INCY

Incyte

$82.37

-3.2 (-3.74%)

, LLY

Eli Lilly

$110.50

-1.13 (-1.01%)

14:58
08/23/19
08/23
14:58
08/23/19
14:58
Hot Stocks
Eli Lilly, Incyte announce baricitinib meets primary endpoint in Phase 3 trial »

Eli Lilly (LLY) and…

INCY

Incyte

$82.37

-3.2 (-3.74%)

LLY

Eli Lilly

$110.50

-1.13 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

  • 23

    Oct

EPD

Enterprise Products

$28.35

-0.605 (-2.09%)

14:55
08/23/19
08/23
14:55
08/23/19
14:55
Options
Enterprise Products put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

LGF.A

Lionsgate

$10.52

-0.28 (-2.59%)

, LGF.B

Lionsgate

$10.01

-0.205 (-2.01%)

14:54
08/23/19
08/23
14:54
08/23/19
14:54
On The Fly
Box Office Battle: 'Angel has Fallen' looking to swoop into top spot »

Welcome to "Box Office…

LGF.A

Lionsgate

$10.52

-0.28 (-2.59%)

LGF.B

Lionsgate

$10.01

-0.205 (-2.01%)

SNE

Sony

$53.87

-0.91 (-1.66%)

CMCSA

Comcast

$42.75

-1.01 (-2.31%)

CMCSK

Comcast

$0.00

(0.00%)

T

AT&T

$34.95

-0.44 (-1.24%)

CBS

CBS

$42.02

-1.43 (-3.29%)

DIS

Disney

$133.09

-2.98 (-2.19%)

VIA

Viacom

$27.31

-0.28 (-1.01%)

VIAB

Viacom

$25.01

-0.85 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 05

    Sep

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 23

    Oct

  • 27

    Oct

QSR

Restaurant Brands

$76.37

0.94 (1.25%)

14:45
08/23/19
08/23
14:45
08/23/19
14:45
Options
Restaurant Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
08/23/19
08/23
14:45
08/23/19
14:45
General news
Fed funds futures surge on the downdraft in stocks »

Fed funds futures surge…

OSW

OneSpaWorld

$15.84

-0.22 (-1.37%)

14:41
08/23/19
08/23
14:41
08/23/19
14:41
Conference/Events
OneSpaWorld management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

OPRX

OptimizeRx

$15.16

-0.39 (-2.51%)

14:38
08/23/19
08/23
14:38
08/23/19
14:38
Conference/Events
OptimizeRx management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 12

    Sep

APPN

Appian

$60.63

0.29 (0.48%)

14:37
08/23/19
08/23
14:37
08/23/19
14:37
Conference/Events
Appian management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 27

    Aug

ET

Energy Transfer LP

$13.35

-0.31 (-2.27%)

14:35
08/23/19
08/23
14:35
08/23/19
14:35
Options
Energy Transfer put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$17.04

0.05 (0.29%)

14:25
08/23/19
08/23
14:25
08/23/19
14:25
Options
Nektar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

14:20
08/23/19
08/23
14:20
08/23/19
14:20
General news
Treasury Action: yields remain sharply lower on a flight to safety »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/23/19
08/23
14:17
08/23/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$43.19

-1.24 (-2.79%)

, DIS

Disney

$133.27

-2.8 (-2.06%)

14:16
08/23/19
08/23
14:16
08/23/19
14:16
Periodicals
Sinclair CEO eyes more regional sports network acquisitions, WSJ reports »

Sinclair Broadcast (SBGI)…

SBGI

Sinclair Broadcast

$43.19

-1.24 (-2.79%)

DIS

Disney

$133.27

-2.8 (-2.06%)

T

AT&T

$34.97

-0.425 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 23

    Sep

  • 23

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/23/19
08/23
14:16
08/23/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$95.83

-3.315 (-3.34%)

14:15
08/23/19
08/23
14:15
08/23/19
14:15
Options
Diamondback Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 11

    Sep

14:10
08/23/19
08/23
14:10
08/23/19
14:10
General news
Action Economics Survey results: »

Action Economics Survey…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.